Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 354 | 2025 | 11220 | 18.850 |
Why?
|
Androgen Antagonists | 94 | 2024 | 1421 | 12.410 |
Why?
|
Prostatectomy | 92 | 2024 | 1841 | 7.880 |
Why?
|
Brachytherapy | 69 | 2021 | 1226 | 7.860 |
Why?
|
Prostate-Specific Antigen | 87 | 2024 | 2487 | 6.980 |
Why?
|
Antineoplastic Agents, Hormonal | 34 | 2023 | 1536 | 4.320 |
Why?
|
SEER Program | 78 | 2020 | 1474 | 4.200 |
Why?
|
Salvage Therapy | 24 | 2020 | 1277 | 3.380 |
Why?
|
Neoplasm Recurrence, Local | 40 | 2022 | 9433 | 2.380 |
Why?
|
Prostate | 35 | 2024 | 1780 | 2.080 |
Why?
|
Healthcare Disparities | 28 | 2023 | 3412 | 2.020 |
Why?
|
Watchful Waiting | 17 | 2019 | 499 | 1.890 |
Why?
|
Male | 423 | 2025 | 364870 | 1.860 |
Why?
|
Kallikreins | 9 | 2020 | 219 | 1.830 |
Why?
|
Adenocarcinoma | 25 | 2021 | 6404 | 1.800 |
Why?
|
Neoplasm Staging | 65 | 2024 | 11254 | 1.780 |
Why?
|
Radiation Injuries | 13 | 2019 | 1204 | 1.730 |
Why?
|
Radiation Oncology | 14 | 2020 | 572 | 1.730 |
Why?
|
Aged | 274 | 2025 | 171544 | 1.700 |
Why?
|
Radiosurgery | 13 | 2023 | 1346 | 1.700 |
Why?
|
Radiotherapy | 21 | 2020 | 1509 | 1.480 |
Why?
|
Cancer Care Facilities | 8 | 2020 | 424 | 1.380 |
Why?
|
Orchiectomy | 10 | 2019 | 466 | 1.370 |
Why?
|
Humans | 469 | 2025 | 768298 | 1.300 |
Why?
|
Middle Aged | 225 | 2025 | 223463 | 1.280 |
Why?
|
Radiotherapy, Adjuvant | 20 | 2020 | 1794 | 1.280 |
Why?
|
Travel | 4 | 2021 | 800 | 1.160 |
Why?
|
Radiotherapy Dosage | 32 | 2020 | 2920 | 1.120 |
Why?
|
Risk Assessment | 50 | 2021 | 24316 | 1.100 |
Why?
|
Gonadotropin-Releasing Hormone | 10 | 2018 | 1149 | 1.100 |
Why?
|
Proportional Hazards Models | 47 | 2021 | 12557 | 1.090 |
Why?
|
Urology | 11 | 2017 | 411 | 1.070 |
Why?
|
United States | 119 | 2023 | 73144 | 1.040 |
Why?
|
Genomics | 15 | 2025 | 5916 | 0.970 |
Why?
|
Rectum | 6 | 2017 | 900 | 0.960 |
Why?
|
Neoplasms | 33 | 2023 | 22389 | 0.960 |
Why?
|
Radiotherapy, Intensity-Modulated | 14 | 2021 | 811 | 0.950 |
Why?
|
Quality of Life | 22 | 2024 | 13499 | 0.940 |
Why?
|
Lymphatic Metastasis | 13 | 2021 | 2924 | 0.870 |
Why?
|
Marital Status | 7 | 2016 | 426 | 0.870 |
Why?
|
Prognosis | 62 | 2025 | 30020 | 0.850 |
Why?
|
Risk Factors | 84 | 2024 | 74954 | 0.840 |
Why?
|
Practice Guidelines as Topic | 17 | 2020 | 7453 | 0.820 |
Why?
|
Aged, 80 and over | 76 | 2022 | 59683 | 0.770 |
Why?
|
Insurance Coverage | 8 | 2021 | 1946 | 0.760 |
Why?
|
Medically Uninsured | 6 | 2021 | 841 | 0.750 |
Why?
|
Tosyl Compounds | 4 | 2021 | 115 | 0.720 |
Why?
|
Leuprolide | 4 | 2018 | 313 | 0.710 |
Why?
|
Early Detection of Cancer | 15 | 2021 | 3236 | 0.710 |
Why?
|
Randomized Controlled Trials as Topic | 25 | 2024 | 10377 | 0.700 |
Why?
|
Survival Analysis | 27 | 2023 | 10117 | 0.700 |
Why?
|
Urogenital Neoplasms | 2 | 2018 | 133 | 0.690 |
Why?
|
Databases, Factual | 22 | 2020 | 8072 | 0.690 |
Why?
|
Logistic Models | 27 | 2020 | 13323 | 0.670 |
Why?
|
Follow-Up Studies | 56 | 2023 | 39405 | 0.670 |
Why?
|
Health Status Disparities | 6 | 2023 | 1882 | 0.660 |
Why?
|
Estrogens | 2 | 2018 | 1534 | 0.660 |
Why?
|
Insurance, Health | 8 | 2019 | 2518 | 0.660 |
Why?
|
Nitriles | 5 | 2023 | 984 | 0.650 |
Why?
|
Neoplasms, Hormone-Dependent | 5 | 2015 | 410 | 0.650 |
Why?
|
Radiation Protection | 2 | 2013 | 428 | 0.640 |
Why?
|
Pelvis | 10 | 2024 | 738 | 0.640 |
Why?
|
Medical Oncology | 6 | 2020 | 2348 | 0.630 |
Why?
|
Neoplasms, Second Primary | 6 | 2022 | 1060 | 0.620 |
Why?
|
Combined Modality Therapy | 30 | 2024 | 8562 | 0.610 |
Why?
|
Multivariate Analysis | 25 | 2020 | 12092 | 0.610 |
Why?
|
Retrospective Studies | 81 | 2024 | 81768 | 0.600 |
Why?
|
Treatment Outcome | 69 | 2021 | 65365 | 0.600 |
Why?
|
Coronavirus | 1 | 2020 | 156 | 0.600 |
Why?
|
Neoplasm Metastasis | 21 | 2021 | 4921 | 0.600 |
Why?
|
Socioeconomic Factors | 16 | 2020 | 7861 | 0.600 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2021 | 417 | 0.600 |
Why?
|
Survival Rate | 33 | 2021 | 12870 | 0.590 |
Why?
|
Testicular Neoplasms | 7 | 2019 | 805 | 0.590 |
Why?
|
Divorce | 1 | 2018 | 78 | 0.590 |
Why?
|
Anilides | 4 | 2021 | 414 | 0.590 |
Why?
|
Carcinoma, Renal Cell | 11 | 2019 | 3199 | 0.580 |
Why?
|
Urogenital System | 2 | 2023 | 88 | 0.570 |
Why?
|
Cryotherapy | 6 | 2020 | 160 | 0.570 |
Why?
|
Radiotherapy, Conformal | 7 | 2019 | 549 | 0.570 |
Why?
|
Urinary Bladder Neoplasms | 9 | 2021 | 2256 | 0.560 |
Why?
|
Age Factors | 27 | 2020 | 18472 | 0.550 |
Why?
|
Disease-Free Survival | 20 | 2024 | 6856 | 0.550 |
Why?
|
Health Services Accessibility | 9 | 2022 | 5511 | 0.550 |
Why?
|
Testosterone | 7 | 2024 | 2493 | 0.540 |
Why?
|
Lymph Nodes | 11 | 2024 | 3471 | 0.520 |
Why?
|
Cohort Studies | 40 | 2023 | 41791 | 0.520 |
Why?
|
Cause of Death | 12 | 2019 | 3728 | 0.510 |
Why?
|
Patient Selection | 11 | 2020 | 4265 | 0.510 |
Why?
|
Kidney Neoplasms | 11 | 2019 | 4301 | 0.500 |
Why?
|
Information Management | 1 | 2015 | 100 | 0.490 |
Why?
|
Incidence | 23 | 2023 | 21544 | 0.490 |
Why?
|
Antineoplastic Agents | 21 | 2024 | 13696 | 0.480 |
Why?
|
Income | 7 | 2016 | 1877 | 0.480 |
Why?
|
Regression Analysis | 11 | 2019 | 6350 | 0.480 |
Why?
|
Myocardial Infarction | 5 | 2014 | 11515 | 0.480 |
Why?
|
Risk | 19 | 2021 | 9635 | 0.470 |
Why?
|
Kaplan-Meier Estimate | 23 | 2019 | 6541 | 0.460 |
Why?
|
Eligibility Determination | 1 | 2018 | 421 | 0.460 |
Why?
|
Odds Ratio | 16 | 2020 | 9681 | 0.460 |
Why?
|
Organs at Risk | 3 | 2020 | 368 | 0.450 |
Why?
|
Seminoma | 4 | 2019 | 136 | 0.450 |
Why?
|
Endometrial Ablation Techniques | 1 | 2013 | 5 | 0.440 |
Why?
|
Neoadjuvant Therapy | 10 | 2024 | 2909 | 0.430 |
Why?
|
Tumor Burden | 7 | 2024 | 1913 | 0.430 |
Why?
|
Clinical Laboratory Techniques | 2 | 2018 | 749 | 0.430 |
Why?
|
Health Care Costs | 10 | 2022 | 3267 | 0.420 |
Why?
|
Cost of Illness | 6 | 2018 | 1959 | 0.420 |
Why?
|
Magnetic Resonance Imaging | 15 | 2023 | 36849 | 0.420 |
Why?
|
Carcinosarcoma | 1 | 2013 | 108 | 0.420 |
Why?
|
Emotions | 3 | 2014 | 2768 | 0.410 |
Why?
|
Androgens | 9 | 2023 | 1285 | 0.410 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1241 | 0.410 |
Why?
|
Arthritis, Rheumatoid | 2 | 2018 | 3776 | 0.410 |
Why?
|
Postoperative Care | 3 | 2015 | 1479 | 0.400 |
Why?
|
Cystectomy | 5 | 2018 | 645 | 0.400 |
Why?
|
Academic Medical Centers | 4 | 2017 | 2783 | 0.400 |
Why?
|
Prospective Studies | 35 | 2024 | 54921 | 0.400 |
Why?
|
Treatment Refusal | 2 | 2021 | 432 | 0.400 |
Why?
|
Confidence Intervals | 8 | 2020 | 2931 | 0.390 |
Why?
|
Lymph Node Excision | 8 | 2016 | 1274 | 0.390 |
Why?
|
Health Expenditures | 5 | 2022 | 2395 | 0.390 |
Why?
|
Time Factors | 29 | 2024 | 40267 | 0.390 |
Why?
|
Penis | 1 | 2013 | 210 | 0.390 |
Why?
|
Models, Organizational | 1 | 2015 | 548 | 0.380 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3940 | 0.380 |
Why?
|
Depression | 6 | 2020 | 8241 | 0.380 |
Why?
|
Gastrointestinal Tract | 2 | 2024 | 839 | 0.370 |
Why?
|
Thromboembolism | 1 | 2018 | 1004 | 0.370 |
Why?
|
Absorbable Implants | 1 | 2013 | 339 | 0.370 |
Why?
|
Community Health Services | 1 | 2016 | 659 | 0.370 |
Why?
|
Forecasting | 3 | 2016 | 2948 | 0.370 |
Why?
|
Hospital Charges | 3 | 2018 | 351 | 0.360 |
Why?
|
Propensity Score | 13 | 2021 | 1955 | 0.360 |
Why?
|
Vasodilation | 1 | 2015 | 968 | 0.360 |
Why?
|
Hydrogels | 2 | 2013 | 744 | 0.360 |
Why?
|
Geriatric Assessment | 2 | 2017 | 1422 | 0.350 |
Why?
|
Nephrectomy | 5 | 2018 | 949 | 0.340 |
Why?
|
Clinical Trials as Topic | 6 | 2020 | 8051 | 0.340 |
Why?
|
Carcinoma | 4 | 2023 | 2340 | 0.340 |
Why?
|
Information Dissemination | 2 | 2015 | 1137 | 0.340 |
Why?
|
Guidelines as Topic | 2 | 2015 | 1397 | 0.340 |
Why?
|
Periodicals as Topic | 2 | 2018 | 1469 | 0.330 |
Why?
|
Health Literacy | 1 | 2015 | 468 | 0.330 |
Why?
|
Seminal Vesicles | 3 | 2018 | 102 | 0.330 |
Why?
|
Edema | 1 | 2013 | 766 | 0.320 |
Why?
|
Cardiovascular Diseases | 8 | 2023 | 15652 | 0.320 |
Why?
|
S-Phase Kinase-Associated Proteins | 1 | 2009 | 89 | 0.320 |
Why?
|
Patient Acceptance of Health Care | 4 | 2021 | 3230 | 0.320 |
Why?
|
Dementia | 3 | 2019 | 2728 | 0.320 |
Why?
|
Receptors, Progesterone | 4 | 2012 | 1145 | 0.320 |
Why?
|
Colonic Neoplasms | 4 | 2023 | 2542 | 0.320 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 8 | 2023 | 1679 | 0.310 |
Why?
|
Hospital Costs | 4 | 2018 | 957 | 0.310 |
Why?
|
Patient Participation | 1 | 2018 | 1448 | 0.310 |
Why?
|
Adult | 68 | 2022 | 223622 | 0.310 |
Why?
|
Patient Preference | 1 | 2016 | 947 | 0.310 |
Why?
|
Gene Expression Profiling | 7 | 2024 | 9508 | 0.310 |
Why?
|
Penile Neoplasms | 2 | 2020 | 158 | 0.310 |
Why?
|
Robotics | 5 | 2014 | 817 | 0.310 |
Why?
|
Breast Neoplasms | 17 | 2025 | 21163 | 0.310 |
Why?
|
International Cooperation | 1 | 2015 | 1438 | 0.300 |
Why?
|
Terminology as Topic | 1 | 2015 | 1539 | 0.300 |
Why?
|
Urban Population | 1 | 2016 | 2045 | 0.300 |
Why?
|
Diphosphonates | 1 | 2012 | 635 | 0.290 |
Why?
|
Biopsy | 8 | 2023 | 6808 | 0.290 |
Why?
|
Medical Informatics | 1 | 2015 | 739 | 0.290 |
Why?
|
Weight Gain | 2 | 2017 | 2358 | 0.290 |
Why?
|
Patient Protection and Affordable Care Act | 5 | 2021 | 1189 | 0.290 |
Why?
|
Radiotherapy, High-Energy | 3 | 2014 | 228 | 0.290 |
Why?
|
Depressive Disorder | 2 | 2017 | 3736 | 0.280 |
Why?
|
Digital Rectal Examination | 2 | 2017 | 42 | 0.280 |
Why?
|
Biopsy, Needle | 3 | 2017 | 1627 | 0.280 |
Why?
|
Uterine Neoplasms | 3 | 2017 | 1426 | 0.270 |
Why?
|
Disease Progression | 13 | 2021 | 13646 | 0.270 |
Why?
|
Imidazoles | 1 | 2012 | 1168 | 0.270 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3242 | 0.270 |
Why?
|
Polyethylene Glycols | 1 | 2012 | 1195 | 0.260 |
Why?
|
Geography | 3 | 2021 | 654 | 0.260 |
Why?
|
Minority Health | 2 | 2019 | 79 | 0.260 |
Why?
|
Diffusion of Innovation | 1 | 2011 | 732 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3118 | 0.260 |
Why?
|
Chemotherapy, Adjuvant | 11 | 2019 | 3553 | 0.260 |
Why?
|
Protons | 2 | 2008 | 1112 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3241 | 0.260 |
Why?
|
Anxiety | 3 | 2021 | 4675 | 0.260 |
Why?
|
Carcinoma in Situ | 2 | 2023 | 789 | 0.250 |
Why?
|
Organ Size | 5 | 2020 | 2268 | 0.250 |
Why?
|
Body Mass Index | 6 | 2017 | 13050 | 0.250 |
Why?
|
Patient Admission | 3 | 2018 | 1367 | 0.250 |
Why?
|
Female | 79 | 2025 | 397050 | 0.250 |
Why?
|
Quality of Health Care | 3 | 2019 | 4339 | 0.250 |
Why?
|
Receptors, Estrogen | 4 | 2012 | 2247 | 0.250 |
Why?
|
Rural Population | 1 | 2016 | 2318 | 0.250 |
Why?
|
Bone Density Conservation Agents | 1 | 2012 | 797 | 0.240 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2019 | 2331 | 0.240 |
Why?
|
Hepatitis C, Chronic | 3 | 2018 | 1031 | 0.240 |
Why?
|
Immunocompetence | 1 | 2005 | 138 | 0.240 |
Why?
|
Pandemics | 3 | 2021 | 8750 | 0.230 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2025 | 165 | 0.230 |
Why?
|
Receptors, Androgen | 3 | 2020 | 1083 | 0.230 |
Why?
|
Hepatitis B, Chronic | 2 | 2019 | 410 | 0.230 |
Why?
|
Developing Countries | 2 | 2019 | 2903 | 0.230 |
Why?
|
Registries | 7 | 2019 | 8378 | 0.230 |
Why?
|
Invasive Pulmonary Aspergillosis | 1 | 2023 | 18 | 0.220 |
Why?
|
Internet | 2 | 2020 | 3107 | 0.220 |
Why?
|
Anxiety Disorders | 1 | 2015 | 2754 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2024 | 8628 | 0.220 |
Why?
|
Liver Cirrhosis | 3 | 2018 | 1957 | 0.210 |
Why?
|
Iodine Radioisotopes | 3 | 2017 | 1035 | 0.210 |
Why?
|
Patient Satisfaction | 2 | 2013 | 3485 | 0.210 |
Why?
|
Receptor, erbB-2 | 4 | 2012 | 2588 | 0.210 |
Why?
|
Bone Diseases, Metabolic | 2 | 2019 | 411 | 0.210 |
Why?
|
Endothelium, Vascular | 1 | 2015 | 4427 | 0.210 |
Why?
|
Ultrasonography | 3 | 2016 | 6001 | 0.210 |
Why?
|
Treatment Failure | 6 | 2019 | 2664 | 0.210 |
Why?
|
Lymphatic Irradiation | 3 | 2024 | 115 | 0.210 |
Why?
|
Liver Neoplasms | 5 | 2019 | 4360 | 0.210 |
Why?
|
Antiviral Agents | 4 | 2023 | 3064 | 0.210 |
Why?
|
Overweight | 1 | 2014 | 2445 | 0.210 |
Why?
|
Predictive Value of Tests | 9 | 2018 | 15455 | 0.200 |
Why?
|
Magnetic Resonance Imaging, Interventional | 2 | 2018 | 195 | 0.200 |
Why?
|
Biomedical Research | 2 | 2015 | 3464 | 0.200 |
Why?
|
Guideline Adherence | 4 | 2019 | 2240 | 0.200 |
Why?
|
Androstenes | 1 | 2023 | 186 | 0.200 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2021 | 2044 | 0.200 |
Why?
|
Herpes Genitalis | 1 | 2023 | 149 | 0.200 |
Why?
|
Phenylthiohydantoin | 1 | 2023 | 208 | 0.200 |
Why?
|
Hospitals | 5 | 2019 | 3905 | 0.200 |
Why?
|
Laparoscopy | 5 | 2017 | 2034 | 0.200 |
Why?
|
Mastectomy, Segmental | 6 | 2018 | 961 | 0.200 |
Why?
|
Medicaid | 3 | 2021 | 2842 | 0.190 |
Why?
|
Dose-Response Relationship, Radiation | 4 | 2018 | 881 | 0.190 |
Why?
|
Neoplasm Proteins | 3 | 2020 | 3609 | 0.190 |
Why?
|
Stroke | 2 | 2014 | 9742 | 0.190 |
Why?
|
Life Expectancy | 4 | 2019 | 1249 | 0.190 |
Why?
|
Neoplasm Invasiveness | 10 | 2021 | 3631 | 0.190 |
Why?
|
Gastrointestinal Diseases | 3 | 2024 | 1207 | 0.190 |
Why?
|
Metal Nanoparticles | 2 | 2017 | 405 | 0.190 |
Why?
|
Coronary Artery Bypass | 1 | 2010 | 2194 | 0.190 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 664 | 0.190 |
Why?
|
Diagnostic Imaging | 6 | 2023 | 3541 | 0.190 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2005 | 646 | 0.180 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2017 | 494 | 0.180 |
Why?
|
Medicare | 11 | 2023 | 6881 | 0.180 |
Why?
|
Michigan | 1 | 2021 | 341 | 0.180 |
Why?
|
Flutamide | 2 | 2012 | 95 | 0.180 |
Why?
|
Comorbidity | 9 | 2018 | 10588 | 0.180 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2015 | 2066 | 0.180 |
Why?
|
Mental Health Services | 3 | 2020 | 1731 | 0.180 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2018 | 799 | 0.170 |
Why?
|
Consensus | 3 | 2024 | 3212 | 0.170 |
Why?
|
Radium | 1 | 2020 | 72 | 0.170 |
Why?
|
Feasibility Studies | 5 | 2023 | 5311 | 0.170 |
Why?
|
Gene Amplification | 1 | 2025 | 1090 | 0.170 |
Why?
|
Heart Failure | 4 | 2014 | 11860 | 0.170 |
Why?
|
Coronary Disease | 1 | 2014 | 5926 | 0.170 |
Why?
|
Penile Erection | 2 | 2018 | 101 | 0.170 |
Why?
|
Radiometry | 4 | 2016 | 816 | 0.170 |
Why?
|
Nomograms | 3 | 2020 | 236 | 0.170 |
Why?
|
Hemibody Irradiation | 1 | 2019 | 4 | 0.170 |
Why?
|
Educational Status | 4 | 2016 | 2518 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2024 | 3981 | 0.170 |
Why?
|
Information Seeking Behavior | 1 | 2020 | 116 | 0.160 |
Why?
|
Surgery, Computer-Assisted | 3 | 2012 | 1006 | 0.160 |
Why?
|
Urethra | 3 | 2021 | 406 | 0.160 |
Why?
|
Health Status | 2 | 2010 | 4094 | 0.160 |
Why?
|
Respiratory Tract Infections | 2 | 2018 | 1014 | 0.160 |
Why?
|
Inpatients | 3 | 2018 | 2569 | 0.160 |
Why?
|
Bone Marrow Examination | 1 | 1999 | 154 | 0.160 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2021 | 555 | 0.160 |
Why?
|
Delphi Technique | 3 | 2024 | 888 | 0.160 |
Why?
|
Disease Management | 6 | 2020 | 2536 | 0.160 |
Why?
|
Protein Kinase Inhibitors | 5 | 2015 | 5707 | 0.160 |
Why?
|
Bone Neoplasms | 3 | 2017 | 2565 | 0.160 |
Why?
|
Taxoids | 2 | 2024 | 668 | 0.150 |
Why?
|
Neuropeptide Y | 1 | 2019 | 194 | 0.150 |
Why?
|
History, 21st Century | 4 | 2019 | 1575 | 0.150 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 2 | 2020 | 43 | 0.150 |
Why?
|
Genetic Association Studies | 3 | 2018 | 2741 | 0.150 |
Why?
|
Lymphoma, B-Cell | 1 | 2005 | 945 | 0.150 |
Why?
|
Methotrexate | 1 | 2005 | 1722 | 0.150 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2019 | 112 | 0.150 |
Why?
|
Benzamides | 1 | 2023 | 1380 | 0.150 |
Why?
|
Advisory Committees | 2 | 2019 | 797 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2020 | 386 | 0.150 |
Why?
|
Proctoscopy | 1 | 2017 | 40 | 0.150 |
Why?
|
Hepatitis C | 2 | 2018 | 1593 | 0.140 |
Why?
|
Self-Help Devices | 1 | 2018 | 62 | 0.140 |
Why?
|
Prostatic Diseases | 1 | 2017 | 57 | 0.140 |
Why?
|
Patient Care Planning | 3 | 2015 | 904 | 0.140 |
Why?
|
Equipment and Supplies | 1 | 2020 | 273 | 0.140 |
Why?
|
Hospital Mortality | 3 | 2021 | 5367 | 0.140 |
Why?
|
Phenylurea Compounds | 1 | 2020 | 529 | 0.140 |
Why?
|
Hormones | 4 | 2023 | 870 | 0.140 |
Why?
|
Perception | 2 | 2014 | 1206 | 0.140 |
Why?
|
Health Policy | 2 | 2023 | 2698 | 0.140 |
Why?
|
Leukemia | 2 | 2002 | 1526 | 0.140 |
Why?
|
Cost-Benefit Analysis | 6 | 2017 | 5538 | 0.140 |
Why?
|
Acute Disease | 4 | 2021 | 7242 | 0.140 |
Why?
|
Laryngeal Neoplasms | 1 | 2020 | 515 | 0.140 |
Why?
|
Postoperative Complications | 4 | 2017 | 15854 | 0.140 |
Why?
|
Financial Management | 1 | 2018 | 161 | 0.130 |
Why?
|
History, 20th Century | 4 | 2019 | 2771 | 0.130 |
Why?
|
Immunity | 1 | 2022 | 1003 | 0.130 |
Why?
|
Marriage | 1 | 2018 | 352 | 0.130 |
Why?
|
Colorectal Neoplasms | 8 | 2021 | 6969 | 0.130 |
Why?
|
Chi-Square Distribution | 5 | 2018 | 3438 | 0.130 |
Why?
|
Fee-for-Service Plans | 2 | 2020 | 714 | 0.130 |
Why?
|
Pain Perception | 1 | 2017 | 198 | 0.130 |
Why?
|
Databases, Nucleic Acid | 1 | 2017 | 204 | 0.130 |
Why?
|
Pelvic Neoplasms | 1 | 2017 | 250 | 0.130 |
Why?
|
Anus Neoplasms | 1 | 2019 | 337 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4069 | 0.130 |
Why?
|
Kidney Function Tests | 1 | 2018 | 681 | 0.130 |
Why?
|
Morbidity | 3 | 2019 | 1758 | 0.130 |
Why?
|
International Classification of Diseases | 1 | 2021 | 924 | 0.130 |
Why?
|
Fetal Blood | 1 | 2002 | 1361 | 0.130 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 300 | 0.130 |
Why?
|
Nonsteroidal Anti-Androgens | 1 | 2015 | 9 | 0.120 |
Why?
|
Mutation | 7 | 2023 | 30230 | 0.120 |
Why?
|
Carcinoma, Embryonal | 1 | 2015 | 36 | 0.120 |
Why?
|
Evidence-Based Medicine | 7 | 2017 | 3707 | 0.120 |
Why?
|
Pathology, Clinical | 1 | 1999 | 376 | 0.120 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2661 | 0.120 |
Why?
|
Patient Care | 1 | 2021 | 629 | 0.120 |
Why?
|
Cryptochromes | 1 | 2015 | 49 | 0.120 |
Why?
|
DNA Repair | 3 | 2023 | 2050 | 0.120 |
Why?
|
Organizations, Nonprofit | 1 | 2015 | 105 | 0.120 |
Why?
|
Demography | 2 | 2018 | 1642 | 0.120 |
Why?
|
Social Class | 3 | 2019 | 2008 | 0.120 |
Why?
|
Urothelium | 1 | 2017 | 275 | 0.120 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1078 | 0.120 |
Why?
|
Internationality | 1 | 2020 | 1008 | 0.120 |
Why?
|
Preventive Health Services | 1 | 2019 | 568 | 0.120 |
Why?
|
Software Validation | 1 | 2014 | 59 | 0.120 |
Why?
|
Erythropoiesis | 1 | 2018 | 693 | 0.120 |
Why?
|
Lymphocytes | 1 | 2002 | 2610 | 0.120 |
Why?
|
Neuropeptides | 1 | 2020 | 950 | 0.120 |
Why?
|
Accidents | 1 | 2015 | 164 | 0.120 |
Why?
|
Gold | 2 | 2017 | 488 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 4 | 2018 | 18047 | 0.120 |
Why?
|
Technology Assessment, Biomedical | 1 | 2017 | 309 | 0.120 |
Why?
|
Exercise Therapy | 1 | 2021 | 941 | 0.120 |
Why?
|
Androgen Receptor Antagonists | 1 | 2015 | 125 | 0.120 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2015 | 93 | 0.120 |
Why?
|
Cryosurgery | 2 | 2011 | 477 | 0.110 |
Why?
|
Goserelin | 1 | 2014 | 126 | 0.110 |
Why?
|
Drug Implants | 1 | 2014 | 230 | 0.110 |
Why?
|
Insurance Benefits | 1 | 2016 | 187 | 0.110 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1727 | 0.110 |
Why?
|
Needles | 1 | 2017 | 461 | 0.110 |
Why?
|
Erythropoietin | 1 | 2018 | 719 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2016 | 16027 | 0.110 |
Why?
|
Leukocyte Count | 1 | 2018 | 1605 | 0.110 |
Why?
|
Urinary Incontinence | 2 | 2009 | 496 | 0.110 |
Why?
|
Gynecomastia | 1 | 2014 | 88 | 0.110 |
Why?
|
Brain Neoplasms | 3 | 2018 | 9197 | 0.110 |
Why?
|
Referral and Consultation | 4 | 2014 | 3627 | 0.110 |
Why?
|
Radiation Dosage | 5 | 2021 | 1973 | 0.110 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 469 | 0.110 |
Why?
|
California | 4 | 2018 | 1443 | 0.110 |
Why?
|
Ultrasound, High-Intensity Focused, Transrectal | 1 | 2013 | 6 | 0.110 |
Why?
|
Suicide | 2 | 2015 | 1607 | 0.110 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 657 | 0.110 |
Why?
|
Linear Models | 4 | 2020 | 5878 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2025 | 5422 | 0.110 |
Why?
|
Adrenocortical Carcinoma | 1 | 2014 | 88 | 0.110 |
Why?
|
Sex Distribution | 2 | 2019 | 2281 | 0.110 |
Why?
|
Health Resources | 1 | 2020 | 950 | 0.110 |
Why?
|
Diagnosis-Related Groups | 1 | 2015 | 448 | 0.110 |
Why?
|
Heart Diseases | 2 | 2019 | 2819 | 0.110 |
Why?
|
Survival | 1 | 2013 | 160 | 0.110 |
Why?
|
Brachial Artery | 1 | 2015 | 373 | 0.110 |
Why?
|
Africa | 1 | 2015 | 726 | 0.110 |
Why?
|
Mortality | 4 | 2019 | 2917 | 0.110 |
Why?
|
Arabidopsis Proteins | 1 | 2015 | 264 | 0.110 |
Why?
|
Carcinoma, Basal Cell | 1 | 2018 | 562 | 0.110 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2018 | 936 | 0.110 |
Why?
|
Recurrence | 5 | 2010 | 8501 | 0.110 |
Why?
|
Certificate of Need | 1 | 2012 | 12 | 0.110 |
Why?
|
Community Health Centers | 1 | 2017 | 469 | 0.110 |
Why?
|
Biocompatible Materials | 1 | 2021 | 1703 | 0.110 |
Why?
|
Muscle, Smooth | 1 | 2017 | 930 | 0.110 |
Why?
|
Capacity Building | 1 | 2015 | 265 | 0.110 |
Why?
|
Genetic Markers | 1 | 2019 | 2604 | 0.100 |
Why?
|
Infratentorial Neoplasms | 1 | 2013 | 99 | 0.100 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2014 | 161 | 0.100 |
Why?
|
Neutropenia | 1 | 2018 | 893 | 0.100 |
Why?
|
Decision Support Techniques | 2 | 2015 | 2005 | 0.100 |
Why?
|
Survivors | 3 | 2020 | 2382 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.100 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 159 | 0.100 |
Why?
|
Chromosome Disorders | 1 | 2015 | 499 | 0.100 |
Why?
|
Erectile Dysfunction | 3 | 2011 | 445 | 0.100 |
Why?
|
Creatinine | 1 | 2018 | 1915 | 0.100 |
Why?
|
Superoxide Dismutase | 1 | 2015 | 596 | 0.100 |
Why?
|
Hepatitis B | 1 | 2017 | 707 | 0.100 |
Why?
|
Neoplasm, Residual | 1 | 2017 | 1019 | 0.100 |
Why?
|
DNA Damage | 3 | 2016 | 2459 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1185 | 0.100 |
Why?
|
Decision Making | 5 | 2021 | 3953 | 0.100 |
Why?
|
Community-Acquired Infections | 1 | 2016 | 473 | 0.100 |
Why?
|
Algorithms | 3 | 2021 | 14154 | 0.100 |
Why?
|
Hospitalization | 6 | 2020 | 10844 | 0.100 |
Why?
|
Hot Flashes | 1 | 2014 | 330 | 0.090 |
Why?
|
Catheters, Indwelling | 1 | 2014 | 436 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2019 | 1376 | 0.090 |
Why?
|
Prevalence | 5 | 2019 | 15868 | 0.090 |
Why?
|
Health Surveys | 3 | 2020 | 4056 | 0.090 |
Why?
|
Endoribonucleases | 1 | 2013 | 230 | 0.090 |
Why?
|
Lung Neoplasms | 5 | 2025 | 13576 | 0.090 |
Why?
|
Urination Disorders | 1 | 2012 | 238 | 0.090 |
Why?
|
Behavioral Risk Factor Surveillance System | 3 | 2016 | 211 | 0.090 |
Why?
|
Rectal Diseases | 1 | 2012 | 141 | 0.090 |
Why?
|
Thoracic Neoplasms | 1 | 2013 | 269 | 0.090 |
Why?
|
Surgery Department, Hospital | 1 | 2012 | 176 | 0.090 |
Why?
|
Population Surveillance | 3 | 2019 | 2598 | 0.090 |
Why?
|
Body Composition | 2 | 2024 | 2461 | 0.090 |
Why?
|
Age of Onset | 2 | 2015 | 3345 | 0.090 |
Why?
|
Ultrasonography, Interventional | 3 | 2016 | 1525 | 0.090 |
Why?
|
RNA-Induced Silencing Complex | 1 | 2010 | 52 | 0.090 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 1337 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4859 | 0.090 |
Why?
|
Patient Compliance | 1 | 2020 | 2693 | 0.090 |
Why?
|
Ependymoma | 1 | 2013 | 328 | 0.090 |
Why?
|
Mass Screening | 4 | 2019 | 5451 | 0.090 |
Why?
|
Colic | 1 | 2010 | 44 | 0.090 |
Why?
|
Models, Economic | 2 | 2012 | 718 | 0.090 |
Why?
|
Comparative Effectiveness Research | 3 | 2021 | 712 | 0.090 |
Why?
|
Health Care Surveys | 5 | 2016 | 2437 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2017 | 2734 | 0.080 |
Why?
|
Gallium Radioisotopes | 2 | 2023 | 195 | 0.080 |
Why?
|
Young Adult | 11 | 2022 | 60048 | 0.080 |
Why?
|
Germ-Line Mutation | 2 | 2015 | 1885 | 0.080 |
Why?
|
Attitude of Health Personnel | 5 | 2015 | 3921 | 0.080 |
Why?
|
Health Services for the Aged | 1 | 2012 | 258 | 0.080 |
Why?
|
Phenotype | 2 | 2018 | 16716 | 0.080 |
Why?
|
Bone Marrow | 2 | 1999 | 2929 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2016 | 1158 | 0.080 |
Why?
|
Osteoporosis | 1 | 2019 | 1606 | 0.080 |
Why?
|
Program Development | 1 | 2015 | 1298 | 0.080 |
Why?
|
Massachusetts | 2 | 2015 | 8902 | 0.080 |
Why?
|
Artifacts | 1 | 2018 | 1930 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3666 | 0.080 |
Why?
|
Light | 1 | 2015 | 1354 | 0.080 |
Why?
|
Muscle Proteins | 1 | 2014 | 1165 | 0.080 |
Why?
|
Brain Stem Neoplasms | 1 | 2011 | 191 | 0.080 |
Why?
|
Leadership | 1 | 2018 | 1395 | 0.080 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2015 | 1320 | 0.080 |
Why?
|
Defecation | 1 | 2010 | 191 | 0.080 |
Why?
|
Wnt1 Protein | 1 | 2008 | 122 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 317 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2018 | 5375 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1076 | 0.080 |
Why?
|
Hormone Replacement Therapy | 1 | 2014 | 756 | 0.080 |
Why?
|
Analysis of Variance | 2 | 2014 | 6238 | 0.070 |
Why?
|
Palmitic Acid | 1 | 2008 | 149 | 0.070 |
Why?
|
Hospice Care | 1 | 2015 | 679 | 0.070 |
Why?
|
Urinary Fistula | 1 | 2007 | 44 | 0.070 |
Why?
|
Angioplasty | 1 | 2010 | 357 | 0.070 |
Why?
|
Metabolic Diseases | 1 | 2014 | 684 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 6319 | 0.070 |
Why?
|
Length of Stay | 6 | 2018 | 6516 | 0.070 |
Why?
|
Male Urogenital Diseases | 1 | 2007 | 48 | 0.070 |
Why?
|
Hypogonadism | 1 | 2014 | 805 | 0.070 |
Why?
|
Unnecessary Procedures | 1 | 2011 | 419 | 0.070 |
Why?
|
Internship and Residency | 2 | 2016 | 5948 | 0.070 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 1756 | 0.070 |
Why?
|
North America | 2 | 2023 | 1290 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1180 | 0.070 |
Why?
|
Abdominal Pain | 2 | 2012 | 1070 | 0.070 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 6034 | 0.070 |
Why?
|
Cytokines | 1 | 2022 | 7443 | 0.070 |
Why?
|
Physicians | 4 | 2020 | 4614 | 0.070 |
Why?
|
Diarrhea | 2 | 2012 | 1320 | 0.070 |
Why?
|
Radiology | 3 | 2021 | 2117 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2015 | 1614 | 0.070 |
Why?
|
C-Peptide | 1 | 2008 | 443 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 937 | 0.070 |
Why?
|
Publication Bias | 2 | 2019 | 159 | 0.070 |
Why?
|
Hepacivirus | 3 | 2018 | 1341 | 0.070 |
Why?
|
Fecal Incontinence | 1 | 2009 | 246 | 0.070 |
Why?
|
Health Services Needs and Demand | 1 | 2014 | 1406 | 0.070 |
Why?
|
Laser Therapy | 1 | 2013 | 1105 | 0.070 |
Why?
|
Sirolimus | 1 | 2013 | 1542 | 0.060 |
Why?
|
Hyperinsulinism | 1 | 2008 | 401 | 0.060 |
Why?
|
Postoperative Period | 3 | 2018 | 1830 | 0.060 |
Why?
|
Interpersonal Relations | 1 | 2013 | 1440 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 2411 | 0.060 |
Why?
|
Neutrophils | 1 | 2018 | 3785 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2013 | 930 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 710 | 0.060 |
Why?
|
DNA Copy Number Variations | 2 | 2025 | 2046 | 0.060 |
Why?
|
Genetic Variation | 2 | 2020 | 6606 | 0.060 |
Why?
|
Utilization Review | 2 | 2016 | 384 | 0.060 |
Why?
|
Vascular Diseases | 1 | 2013 | 1161 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2017 | 15939 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5947 | 0.060 |
Why?
|
Research Design | 2 | 2020 | 6209 | 0.060 |
Why?
|
Health Behavior | 1 | 2016 | 2647 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2002 | 5711 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2015 | 2986 | 0.060 |
Why?
|
Inflammation | 2 | 2022 | 10863 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2015 | 1937 | 0.060 |
Why?
|
Endometrial Neoplasms | 1 | 2013 | 1382 | 0.060 |
Why?
|
Adolescent | 11 | 2022 | 89182 | 0.060 |
Why?
|
Mastectomy | 1 | 2012 | 1851 | 0.060 |
Why?
|
Europe | 2 | 2023 | 3439 | 0.060 |
Why?
|
Cytoplasm | 1 | 2008 | 1500 | 0.060 |
Why?
|
Receptors, CCR10 | 1 | 2023 | 10 | 0.060 |
Why?
|
Sex Factors | 2 | 2016 | 10656 | 0.060 |
Why?
|
United States Department of Veterans Affairs | 2 | 2019 | 940 | 0.050 |
Why?
|
Social Support | 1 | 2013 | 2190 | 0.050 |
Why?
|
Terminal Care | 1 | 2015 | 1773 | 0.050 |
Why?
|
Aspergillus | 1 | 2023 | 95 | 0.050 |
Why?
|
beta Catenin | 1 | 2008 | 1047 | 0.050 |
Why?
|
Body Weight | 1 | 2014 | 4630 | 0.050 |
Why?
|
Middle East | 1 | 2023 | 233 | 0.050 |
Why?
|
Mental Disorders | 2 | 2020 | 6876 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1260 | 0.050 |
Why?
|
Reproducibility of Results | 5 | 2017 | 20224 | 0.050 |
Why?
|
Health Facilities | 2 | 2019 | 577 | 0.050 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1126 | 0.050 |
Why?
|
Age Distribution | 2 | 2019 | 2877 | 0.050 |
Why?
|
Chemokines, CC | 1 | 2023 | 286 | 0.050 |
Why?
|
Poverty | 1 | 2014 | 2721 | 0.050 |
Why?
|
Herpesvirus 2, Human | 1 | 2023 | 191 | 0.050 |
Why?
|
Ischemia | 1 | 2010 | 1900 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7955 | 0.050 |
Why?
|
Cross-Sectional Studies | 6 | 2021 | 26373 | 0.050 |
Why?
|
Tumor Cells, Cultured | 1 | 2009 | 6132 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1943 | 0.050 |
Why?
|
Radioimmunotherapy | 1 | 2021 | 93 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2017 | 876 | 0.050 |
Why?
|
Genome | 2 | 2020 | 1747 | 0.050 |
Why?
|
Obesity | 2 | 2017 | 13082 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2529 | 0.050 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 1998 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5443 | 0.040 |
Why?
|
Primary Health Care | 1 | 2017 | 4748 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2010 | 2060 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5802 | 0.040 |
Why?
|
Peripheral Arterial Disease | 1 | 2012 | 1303 | 0.040 |
Why?
|
Mucous Membrane | 1 | 2023 | 659 | 0.040 |
Why?
|
Self Report | 3 | 2016 | 3766 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 239 | 0.040 |
Why?
|
Stress, Psychological | 3 | 2021 | 4543 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 3722 | 0.040 |
Why?
|
Models, Biological | 2 | 2014 | 9494 | 0.040 |
Why?
|
Equipment Design | 2 | 2017 | 3529 | 0.040 |
Why?
|
Blast Crisis | 1 | 1999 | 102 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2023 | 6670 | 0.040 |
Why?
|
Online Systems | 1 | 2020 | 182 | 0.040 |
Why?
|
Stromal Cells | 1 | 2024 | 1337 | 0.040 |
Why?
|
Selection Bias | 1 | 2020 | 360 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1881 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4647 | 0.040 |
Why?
|
Erythrocyte Count | 1 | 2018 | 157 | 0.040 |
Why?
|
Stents | 1 | 2010 | 3201 | 0.040 |
Why?
|
Glioblastoma | 1 | 2013 | 3526 | 0.040 |
Why?
|
Pakistan | 1 | 2019 | 298 | 0.040 |
Why?
|
Consumer Health Information | 1 | 2020 | 215 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 9063 | 0.040 |
Why?
|
Observer Variation | 1 | 2004 | 2623 | 0.040 |
Why?
|
Brain | 1 | 2005 | 27452 | 0.040 |
Why?
|
False Negative Reactions | 1 | 1999 | 575 | 0.040 |
Why?
|
Guanine | 1 | 2019 | 280 | 0.040 |
Why?
|
Catheter Ablation | 1 | 2011 | 2776 | 0.040 |
Why?
|
Stereotaxic Techniques | 1 | 2020 | 556 | 0.040 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2017 | 90 | 0.040 |
Why?
|
Kinetics | 2 | 2019 | 6334 | 0.040 |
Why?
|
Quality Control | 1 | 2020 | 833 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2011 | 9261 | 0.030 |
Why?
|
Probability | 1 | 2022 | 2482 | 0.030 |
Why?
|
Politics | 1 | 2023 | 821 | 0.030 |
Why?
|
Thrombosis | 1 | 2010 | 2955 | 0.030 |
Why?
|
Standard of Care | 1 | 2021 | 570 | 0.030 |
Why?
|
C-Reactive Protein | 2 | 2022 | 3859 | 0.030 |
Why?
|
Taiwan | 1 | 2017 | 528 | 0.030 |
Why?
|
Korea | 1 | 2015 | 97 | 0.030 |
Why?
|
Philippines | 1 | 2015 | 95 | 0.030 |
Why?
|
Radiography | 3 | 2012 | 6993 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 737 | 0.030 |
Why?
|
Asia | 1 | 2017 | 627 | 0.030 |
Why?
|
Carboplatin | 1 | 2019 | 799 | 0.030 |
Why?
|
Immune System | 1 | 2021 | 801 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2018 | 17132 | 0.030 |
Why?
|
Liver | 2 | 2024 | 7570 | 0.030 |
Why?
|
Ferritins | 1 | 2018 | 601 | 0.030 |
Why?
|
Cystoscopy | 1 | 2015 | 132 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2146 | 0.030 |
Why?
|
Prostatic Hyperplasia | 1 | 2019 | 522 | 0.030 |
Why?
|
Vietnam | 1 | 2015 | 416 | 0.030 |
Why?
|
Chromosome Breakage | 1 | 2015 | 159 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 683 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2020 | 2862 | 0.030 |
Why?
|
Hepatitis B virus | 1 | 2018 | 527 | 0.030 |
Why?
|
Efficiency | 1 | 2017 | 477 | 0.030 |
Why?
|
Gene Expression Regulation, Plant | 1 | 2015 | 211 | 0.030 |
Why?
|
Needs Assessment | 1 | 2020 | 1142 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2016 | 2830 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 985 | 0.030 |
Why?
|
Pain Threshold | 1 | 2017 | 606 | 0.030 |
Why?
|
Antigens, Surface | 1 | 2017 | 1616 | 0.030 |
Why?
|
Cell Cycle | 1 | 2021 | 2934 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2014 | 525 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2023 | 3781 | 0.030 |
Why?
|
Indians, North American | 1 | 2017 | 354 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 12239 | 0.030 |
Why?
|
Role | 1 | 2013 | 176 | 0.030 |
Why?
|
Hemorrhage | 1 | 2004 | 3461 | 0.020 |
Why?
|
ROC Curve | 1 | 2020 | 3622 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2016 | 22292 | 0.020 |
Why?
|
Cost Savings | 1 | 2017 | 915 | 0.020 |
Why?
|
Arabidopsis | 1 | 2015 | 469 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1672 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2022 | 2661 | 0.020 |
Why?
|
Benchmarking | 1 | 2018 | 1058 | 0.020 |
Why?
|
Japan | 1 | 2015 | 1418 | 0.020 |
Why?
|
Family | 1 | 2022 | 3208 | 0.020 |
Why?
|
Office Visits | 1 | 2015 | 596 | 0.020 |
Why?
|
Immunohistochemistry | 3 | 2015 | 11117 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2017 | 1476 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2139 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2014 | 2298 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2013 | 640 | 0.020 |
Why?
|
Child | 4 | 2021 | 80894 | 0.020 |
Why?
|
Critical Illness | 1 | 2023 | 2755 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 20766 | 0.020 |
Why?
|
Mucus | 1 | 2012 | 346 | 0.020 |
Why?
|
Risk Adjustment | 1 | 2014 | 603 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3587 | 0.020 |
Why?
|
Genotype | 2 | 2016 | 13038 | 0.020 |
Why?
|
Axilla | 1 | 2012 | 628 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2950 | 0.020 |
Why?
|
Immobilization | 1 | 2010 | 230 | 0.020 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 4908 | 0.020 |
Why?
|
China | 1 | 2015 | 2389 | 0.020 |
Why?
|
Liver Diseases | 1 | 2018 | 1301 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2012 | 1705 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4981 | 0.020 |
Why?
|
Rotation | 1 | 2010 | 517 | 0.020 |
Why?
|
Boston | 2 | 2012 | 9371 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 1999 | 3712 | 0.020 |
Why?
|
Anticoagulants | 1 | 2004 | 4842 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4120 | 0.020 |
Why?
|
Pelvic Bones | 1 | 2010 | 274 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2015 | 1658 | 0.020 |
Why?
|
Military Personnel | 1 | 2017 | 1265 | 0.020 |
Why?
|
Mice | 3 | 2023 | 82004 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3794 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2015 | 997 | 0.020 |
Why?
|
World Health Organization | 1 | 2013 | 1327 | 0.020 |
Why?
|
Parenteral Nutrition | 1 | 2012 | 663 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2008 | 866 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 1669 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2012 | 1155 | 0.020 |
Why?
|
Subcutaneous Fat | 1 | 2010 | 403 | 0.020 |
Why?
|
Influenza, Human | 1 | 2018 | 1539 | 0.020 |
Why?
|
Photochemotherapy | 1 | 2013 | 830 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3541 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2016 | 2200 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2010 | 887 | 0.020 |
Why?
|
Heart | 1 | 2019 | 4449 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12457 | 0.020 |
Why?
|
Animals | 4 | 2023 | 169322 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2016 | 1813 | 0.020 |
Why?
|
Child, Preschool | 2 | 2013 | 42654 | 0.020 |
Why?
|
Molecular Structure | 1 | 2010 | 1884 | 0.020 |
Why?
|
Arteries | 1 | 2010 | 1126 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 954 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2010 | 740 | 0.020 |
Why?
|
Models, Statistical | 1 | 2020 | 5099 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2017 | 3579 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8730 | 0.020 |
Why?
|
Patient Discharge | 1 | 2018 | 3474 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3267 | 0.010 |
Why?
|
Alleles | 1 | 2016 | 6892 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22355 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10776 | 0.010 |
Why?
|
Femur | 1 | 2010 | 1311 | 0.010 |
Why?
|
DNA Primers | 1 | 2008 | 2823 | 0.010 |
Why?
|
Preoperative Care | 1 | 2013 | 2257 | 0.010 |
Why?
|
Phosphorylation | 1 | 2015 | 8326 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5335 | 0.010 |
Why?
|
Movement | 1 | 2010 | 1490 | 0.010 |
Why?
|
Photons | 1 | 2007 | 594 | 0.010 |
Why?
|
Cognition | 1 | 2020 | 7074 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3230 | 0.010 |
Why?
|
Contrast Media | 1 | 2016 | 5337 | 0.010 |
Why?
|
Critical Care | 1 | 2015 | 2716 | 0.010 |
Why?
|
Societies, Medical | 1 | 2014 | 3960 | 0.010 |
Why?
|
Lung | 1 | 2021 | 10087 | 0.010 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2004 | 344 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 2923 | 0.010 |
Why?
|
Mice, Nude | 1 | 2008 | 3630 | 0.010 |
Why?
|
Clinical Competence | 1 | 2017 | 4847 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14783 | 0.010 |
Why?
|
Patient Readmission | 1 | 2016 | 3312 | 0.010 |
Why?
|
Veterans | 1 | 2015 | 2672 | 0.010 |
Why?
|
Computer Simulation | 1 | 2014 | 6277 | 0.010 |
Why?
|
Software | 1 | 2015 | 4452 | 0.010 |
Why?
|
Urinary Bladder | 1 | 2007 | 1160 | 0.010 |
Why?
|
Recovery of Function | 1 | 2011 | 2990 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14736 | 0.010 |
Why?
|
Quality Improvement | 1 | 2015 | 3858 | 0.010 |
Why?
|
Infant | 1 | 2002 | 36512 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2013 | 4209 | 0.010 |
Why?
|
RNA Interference | 1 | 2008 | 2836 | 0.010 |
Why?
|
Mental Health | 1 | 2014 | 3276 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 3520 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2015 | 10464 | 0.010 |
Why?
|
Fas Ligand Protein | 1 | 1999 | 217 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 1999 | 521 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11854 | 0.010 |
Why?
|
Base Sequence | 1 | 2008 | 12421 | 0.010 |
Why?
|
Heparin | 1 | 2004 | 1636 | 0.010 |
Why?
|
Warfarin | 1 | 2004 | 1493 | 0.010 |
Why?
|
Coculture Techniques | 1 | 1999 | 1342 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 3811 | 0.010 |
Why?
|
Blotting, Western | 1 | 1999 | 5033 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1999 | 5898 | 0.000 |
Why?
|
Hematopoietic Stem Cells | 1 | 1999 | 3407 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1999 | 19019 | 0.000 |
Why?
|
Apoptosis | 1 | 1999 | 9506 | 0.000 |
Why?
|